Current Treatment of In-Stent Restenosis
Current Treatment of In-Stent Restenosis
复制标题
DOI：
10.1016/j.jacc.2014.02.545
复制
发表时间：
2014-06-24
影响因子：
24
通讯作者：
Kastrati, Adnan
中科院分区：
文献类型：
--
作者：
Alfonso, Fernando;Byrne, Robert A.;Kastrati, Adnan
支架内再狭窄(ISR)患者的处理仍然是一个重要的临床问题。尽管药物洗脱支架(DES)极大地降低了ISR的发生率，但DES-ISR的治疗尤其具有挑战性。ISR主要是侵袭性新生内膜增殖的结果，但最近的研究也表明，新生动脉粥样硬化可能在其中起着重要的病理生理作用。冠状动脉内成像提供了独特的洞察力来揭示ISR的基础物质，并可用于指导重复干预。在这篇文章中，我们系统地回顾了目前可用的治疗方法的临床试验数据，包括DES和药物涂层球囊，在裸金属支架或DES中出现ISR的患者。(C)2014年，由美国心脏病学院基金会
Management of patients with in-stent restenosis (ISR) remains an important clinical problem. Although drug-eluting stents (DES) have drastically reduced the incidence of ISR, treatment of DES-ISR is particularly challenging. ISR mainly results from aggressive neointimal proliferation, but recent data also suggest that neoatherosclerosis may play an important pathophysiological role. Intracoronary imaging provides unique insights to unravel the underlying substrate of ISR and may be used to guide repeated interventions. In this paper, we systematically reviewed clinical trial data with currently available therapeutic modalities, including DES and drug-coated balloons, in patients presenting with ISR within bare-metal stents or DES. (c) 2014 by the American College of Cardiology Foundation